Abzena and Mabqi announced a strategic partnership to integrate Mabqi’s LiteMab antibody discovery platform with Abzena’s cell line, process development and GMP manufacturing services. The collaboration aims to shorten timelines from hit identification to preclinical candidate and address multiple biologic modalities including mAbs, fragments, bispecifics and conjugates. Mabqi brings universal and pH‑sensitive libraries and discovery workflows; Abzena contributes downstream development and GMP manufacturing expertise. Executives from both firms highlighted streamlined workflows, shared data, and closer scientific alignment as key advantages for sponsors seeking single‑partner continuity. The tie-up reflects continued market demand for turnkey biologics R&D and manufacturing solutions that reduce transfer risk and compress timelines ahead of IND enabling activities.